Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07046156

Treatment of Overactive Bladder With Anticholinergic Agents

This study aims to evaluate the efficacy and adverse effect incidence of three different anticholinergics (oxybutinin, propiverine, and tolterodine) that are used in children with overactive bladder.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Overactive Bladder Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Lower Urinary Tract Symptoms Male Urogenital Diseases Pathological Conditions, Signs and Symptoms Signs and Symptoms Urinary Bladder Diseases Urinary Bladder, Overactive Urogenital Diseases Urologic Diseases Urological Manifestations

Age range

5 year–17 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Sancaktepe Sehit Prof dr Ilhan Varank Training and Research Hospital

Istanbul, Turkey (Türkiye)

About this study

A total of approximately 150 patients with overactive bladder will be evaluated retrospectively. Clinical and demographic data and voiding diaries of these patients will be evaluated. For this purpose, patients will be divided into mainly three groups according to the anticholinergic agent used.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients diagnosed with overactive bladder
  • Patients treated with an anticholinergic

Exclusion criteria

  • Presence of anatomical or neurological problems
  • Patients with missing data

Treatment and study plan

Oxybutynin Cl

Drug

Oxybutynin in a dose of 0.5 mg/kg will be used in the treatment of overactive bladder

Propiverine

Drug

Propiverine in a dose of 0.8 mg/kg will be used in the treatment of overactive bladder

tolterodine

Drug

Tolterodine in a dose of 0.1 mg/kg will be used in the treatment of overactive bladder

Primary outcomes

  1. Number of patients treated with anticholinergic

    Time frame: 6 months

  2. Number of patients with drug related adverse effects

    Time frame: 1 month

Sponsors and collaborators

Lead sponsor

Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital

Other

Registry information

Official study title

Evaluation of Anticholinergic Treatment Response and Predictive Factors in Pediatric Overactive Bladder

Important dates

Study start
2022
Primary completion
2025
Study completion
2026
First posted
Jul 1, 2025
Registry last updated
Jul 1, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.